The estimated Net Worth of Stephen F Fry is at least $141 Million dollars as of 1 February 2022. Mr. Fry owns over 10,170 units of Lilly(Eli) & Co stock worth over $133,387,233 and over the last 13 years he sold LLY stock worth over $7,447,452. In addition, he makes $0 as Senior Vice President - Human Resources and Diversity at Lilly(Eli) & Co.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Fry LLY stock SEC Form 4 insiders trading
Stephen has made over 19 trades of the Lilly(Eli) & Co stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 10,170 units of LLY stock worth $9,365,451 on 1 February 2022.
The largest trade he's ever made was exercising 17,060 units of Lilly(Eli) & Co stock on 1 February 2018 worth over $15,710,383. On average, Stephen trades about 6,122 units every 108 days since 2012. As of 1 February 2022 he still owns at least 144,846 units of Lilly(Eli) & Co stock.
You can see the complete history of Mr. Fry stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephen Fry biography
Stephen F. Fry serves as Senior Vice President - Human Resources and Diversity of the Company. He was the managing director of Lilly's Australian affiliate from 2004 -- 2007, then served in human resources capacities as executive director for the intercontinental region and Japan until becoming vice president for bio-medicines and emerging markets. He joined Lilly in 1987 as a scientific systems analyst in the company's former Greenfield, Ind. laboratories, moving into human resources in 1992. He assumed a leadership role when he was selected as the director of human resources for Lilly's United Kingdom affiliate in 1998, followed by executive director positions for both Lilly's U.S. affiliate and the pharmaceutical operations area. He has a bachelor's degree in business from the University of Indianapolis.
How old is Stephen Fry?
Stephen Fry is 54, he's been the Senior Vice President - Human Resources and Diversity of Lilly(Eli) & Co since 2011. There are 15 older and 16 younger executives at Lilly(Eli) & Co. The oldest executive at Lilly(Eli) & Co is Kathi Seifert, 71, who is the Independent Director.
What's Stephen Fry's mailing address?
Stephen's mailing address filed with the SEC is Eli Lilly and Company Corporate Center, Indianapolis, Marion County, Indiana, United States.
Insiders trading at Lilly(Eli) & Co
Over the last 20 years, insiders at Lilly(Eli) & Co have traded over $29,994,829,903 worth of Lilly(Eli) & Co stock and bought 73,808 units worth $5,778,435 . The most active insiders traders include Endowment Inc Lilly, R David Hoover, and Lorenzo Tallarigo. On average, Lilly(Eli) & Co executives and independent directors trade stock every 7 days with the average trade being worth of $55,447,708. The most recent stock trade was executed by Endowment Inc Lilly on 3 September 2024, trading 24,084 units of LLY stock currently worth $23,281,762.
What does Lilly(Eli) & Co do?
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.
What does Lilly(Eli) & Co's logo look like?
Complete history of Mr. Fry stock trades at Lilly(Eli) & Co
Lilly(Eli) & Co executives and stock owners
Lilly(Eli) & Co executives and other stock owners filed with the SEC include:
-
David Ricks,
Chairman of the Board, President, Chief Executive Officer -
Joshua Smiley,
Chief Financial Officer, Senior Vice President -
Daniel Skovronsky,
Senior Vice President, Chief Scientific Officer and President, Lilly Research Laboratories -
David A. Ricks,
Chairman, CEO & Pres -
Anat Hakim J.D.,
Sr. VP, Gen. Counsel & Sec. -
Jackson Tai,
Independent Director -
Juan Luciano,
Lead Independent Director -
J. Erik Fyrwald,
Independent Director -
Karen Walker,
Independent Director -
William Kaelin,
Independent Director -
Michael Eskew,
Independent Director -
Jamere Jackson,
Independent Director -
Katherine Baicker,
Independent Director -
Raul Alvarez,
Independent Director -
Kathi Seifert,
Independent Director -
Marschall Runge,
Independent Director -
Carolyn Bertozzi,
Independent Director -
Alfonso Zulueta,
Senior Vice President, President - Lilly International -
Ilya Yuffa,
Senior Vice President and President of Lilly Bio-Medicines -
Anne White,
Senior Vice President, President - Lilly Oncology -
Leigh Pusey,
Senior Vice President - Corporate Affairs and Communications -
Myles O'Neill,
Senior Vice President and President - Manufacturing Operations -
Johna Norton,
Senior Vice President - Global Quality -
Michael Mason,
Senior Vice President and President, Lilly Diabetes -
Patrik Jonsson,
Senior Vice President, President of Lilly USA , and Chief Customer Officer -
Stephen Fry,
Senior Vice President - Human Resources and Diversity -
Anat Hakim,
Senior Vice President, General Counsel -
Melissa Barnes,
Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer -
Aarti Shah,
Senior Vice President - Chief Information and Digital Officer -
Leigh Ann Pusey,
Sr. VP of Corp. Affairs & Communications -
Alonzo Weems,
Sr. VP and Chief Ethics & Compliance Officer -
Diogo Rau,
Sr. VP & Chief Information and Digital Officer -
Kevin Hern,
VP of Investor Relations -
Martin Bott MIBS,
VP of Fin. & Special Projects -
Donald A. Zakrowski,
Chief Accounting Officer & VP of Fin. -
Jacob S. Van Naarden,
Chief Operating Officer of Loxo Oncology -
Anat Ashkenazi,
Sr. VP & CFO -
Eric Dozier,
EVP, HR & Diversity -
Endowment Inc Lilly,
-
Christi Shaw,
SVP and Pres., Lilly Bio-Meds -
Fionnuala M Walsh,
SVP, Global Quality -
Jan M Lundberg,
EVP,Science&Tech and Pres. LRL -
Maria A Crowe,
President, Mfg. Operations -
Ralph Alvarez,
Director -
Michael J Harrington,
Senior VP and General Counsel -
Jeffrey N Simmons,
SVP&Pres.,Elanco Animal Health -
Susan Mahony,
SVP, HR & Diversity -
Barton R Peterson,
Sr. VP, Corp. Affairs & Comm. -
Derica W Rice,
Sr. Vice President and CFO -
Enrique A Conterno,
Sr. VP & Pres., Lilly Diabetes -
Naarden Jacob Van,
EVP & Pres., Loxo@Lilly -
Donald A Zakrowski,
SVP, Finance, & CAO -
Karen N Horn,
Director -
John C Lechleiter,
President and COO -
Alonzo Weems,
EVP, ERM & CECO -
R David Hoover,
Director -
Franklyn G Prendergast,
Director -
Ellen R Marram,
Director -
Douglas R Oberhelman,
Director -
Anne Nobles,
Chief Eth/Cmpl Ofcr & SVP, ERM -
Bryce D. Carmine,
EVP and Pres, Lilly Bio-Meds -
Robert A Armitage,
Sr. VP and General Counsel -
Steven M Paul,
EVP, Science and Technology -
Frank M Deane,
President, Manufacturing -
J Michael Cook,
Director -
Alfred G Gilman,
Director -
Martin S Feldstein,
Director -
Sidney Taurel,
Chairman, President and CEO -
Alex M Ii Azar,
Sr. VP, Corp. Affairs & Comm. -
Gino Santini,
Sr.VP, Corp. Strategy & Policy -
Deirdre P Connelly,
President, Lilly USA -
Anthony John Murphy,
Senior VP, Human Resources -
Jacques Tapiero,
SVP&Pres., Emerging Markets -
Winfried F W Sir Bischoff,
Director -
Arnold C Hanish,
Chief Accounting Officer -
Lorenzo Tallarigo,
President, Internat'l Opers. -
George M C Fisher,
Director -
Scott A Canute,
President, Mfg. Operations -
Charles E Golden,
Exec. Vice President and CFO -
Kimberly H Johnson,
Director -
Anat Ashkenazi,
EVP & CFO -
Diogo Rau,
EVP & CIDO -
Edgardo Hernandez,
EVP & Pres., Mfg. Operations -
Gabrielle Sulzberger,
Director -
Mary Lynne Hedley,
Director -
Melissa Seymour,
EVP, Global Quality